NVO - Novo Nordisk A/S
| Previous close | 56.50 |
| Open | 57.05 |
| Bid | 57.29 x 800 |
| Ask | 57.30 x 800 |
| Day's range | 56.85 - 57.66 |
| 52-week range | 43.60 - 58.01 |
| Volume | 1196368 |
| Avg. volume | 1,416,617 |
| Market cap | 135B |
| Beta (5Y Monthly) | 0.59 |
| PE ratio (TTM) | 23.25 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 1.25 (2.21%) |
| Ex-dividend date | 2019-03-22 |
| 1y target est | N/A |
- Simply Wall St.
What Did Novo Nordisk A/S's (CPH:NOVO B) CEO Take Home Last Year?
In 2017 Lars Jørgensen was appointed CEO of Novo Nordisk A/S (CPH:NOVO B). First, this article will compare CEO...
- Zacks
Novo Nordisk Inks Deal With Dicerna to Develop RNAi Therapies
Novo Nordisk (NVO) inks deal with Dicerna Pharmaceuticals to discover and develop novel therapies for the treatment of liver-related cardio-metabolic diseases.
- Zacks
Here's Why AstraZeneca's (AZN) Shares Are Up Year to Date
AstraZeneca's (AZN) stock is on an upward trajectory this year. Let us take a look at the reasons for the same.
- Zacks
AstraZeneca/Merck's Selumetinib NDA Gets FDA Priority Status
The FDA grants priority review to AstraZeneca (AZN) and Merck's NDA for MEK 1/2 inhibitor, selumetinib. Additionally, Qtrilmet tablets to treat type-II diabetes get approval in the EU.
- Zacks
4 Big Drugmakers to Bet on After a Great Earnings Season
Big drugmakers post better-than-expected Q3 results, leading to rise in share price of most of the companies in the industry.
- Zacks
The Zacks Analyst Blog Highlights: Microsoft, Novartis, Novo Nordisk, Tesla and General Dynamics
The Zacks Analyst Blog Highlights: Microsoft, Novartis, Novo Nordisk, Tesla and General Dynamics
- Zacks
FDA Panel Votes Against Lilly's Jardiance for Type I Diabetes
Eli Lilly (LLY) gets an unfavorable FDA panel vote to expand the label of its type II diabetes medicine Jardiance (2.5 mg) for type I diabetes.
- Zacks
Top Analyst Reports for Microsoft, Novartis & Novo Nordisk
Top Analyst Reports for Microsoft, Novartis & Novo Nordisk
- Zacks
The Zacks Analyst Blog Highlights: Novo Nordisk, Allergan, Sanofi, Novartis and J&J
The Zacks Analyst Blog Highlights: Novo Nordisk, Allergan, Sanofi, Novartis and J&J
- Zacks
Pharma Stock Roundup: AGN, NVO Q3 Earnings, FDA Nod to SNY & NVS' Products
Novo Nordisk (NVO) and Allergan (AGN) release Q3 results. FDA approves Sanofi's quadrivalent flu vaccine for older adults and Novartis' long-acting biosimilar version of Amgen's Neulasta.
- Zacks
Novo Nordisk (NVO) Q3 Earnings Beat Estimates, Revenues Miss
Novo Nordisk (NVO) beats earnings estimates but misses sales estimates in the third quarter of 2019.
- Zacks
The Zacks Analyst Blog Highlights: Citigroup, Novo Nordisk, BP, salesforce.com and TC Energy
The Zacks Analyst Blog Highlights: Citigroup, Novo Nordisk, BP, salesforce.com and TC Energy
- Reuters - UK Focus
UPDATE 2-European shares end week on cheery note after U.S. and Chinese data
European shares clocked their best day in over a week on Friday, as upbeat jobs data from the United States and a surprise bounce in Chinese manufacturing tempered nerves around slowing global growth. U.S. job growth slowed less than expected in October, while a private business survey indicated that China's factory activity unexpectedly expanded at the fastest pace in more than two years last month. The latest data out of China is in contrast to an official survey published on Thursday, which had factory activity shrinking for the sixth straight month in October.
- Reuters
Novo Nordisk nudges up 2019 sales outlook as new drugs excel
Novo Nordisk posted third-quarter operating profit a touch below expectations on Friday on weak insulin sales and impairments, but nudged up its sales outlook on hopes for new type 2 diabetes and obesity drugs. Novo now sees 2019 sales growth at 5-6% versus 4-6% previously, and held its forecast for operating profit growth at 4-6%, both in local currency terms. The world's largest maker of diabetes drugs is betting on new treatments, including a first-of-its-kind tablet, to offset pricing pressure from competing insulins and U.S. lawmakers, who have been critical of rising drug costs.
- Zacks
Top Analyst Reports for Citigroup, Novo Nordisk & BP
Top Analyst Reports for Citigroup, Novo Nordisk & BP
- Simply Wall St.
Can Novo Nordisk A/S's (CPH:NOVO B) ROE Continue To Surpass The Industry Average?
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...
- Zacks
PFE vs. NVO: Which Stock Is the Better Value Option?
PFE vs. NVO: Which Stock Is the Better Value Option?
- Zacks
The Zacks Analyst Blog Highlights: Intel, Oracle, Novo Nordisk, ConocoPhillips and Advanced Micro Devices
The Zacks Analyst Blog Highlights: Intel, Oracle, Novo Nordisk, ConocoPhillips and Advanced Micro Devices
- Zacks
Top Analyst Reports for Intel, Oracle & Novo Nordisk
Top Analyst Reports for Intel, Oracle & Novo Nordisk
- Zacks
The Zacks Analyst Blog Highlights: Novartis, J&J, Pfizer, Novo Nordisk and Glaxo
The Zacks Analyst Blog Highlights: Novartis, J&J, Pfizer, Novo Nordisk and Glaxo
- Zacks
Pharma Stock Roundup: NVS' New Eye Drug Gets FDA Nod, NVO, GSK, PFE Sign Deals
FDA approves Novartis' (NVS) Beovu. J&J (JNJ) files sBLA for Stelara. Pfizer (PFE), Novo Nordisk (NVO) and Glaxo (GSK) announce collaboration deals.
- Zacks
Gilead-Galapagos Report Efficacy & Safety Results on RA Drug
Gilead (GILD) announces 52-week efficacy and safety results on experimental RA drug, filgotinib, from two late-stage studies.
- Zacks
bluebird Inks Genome Editing Research Deal With Novo Nordisk
bluebird (BLUE) signs a collaboration contract with Novo Nordisk to develop next-generation in vivo genome editing therapies for the treatment of genetic disorders including hemophilia.
- Zacks
Novo Nordisk Focuses on Pipeline Development Amid Competition
Novo Nordisk (NVO) has a strong presence in the Diabetes care market and focuses on the development of its pipeline amid competition.
- Zacks
Gilead's Descovy HIV Regimen Gets FDA Nod for Label Expansion
Gilead (GILD) obtains FDA approval for HIV treatment Descovy as a prevention option.
